- 米国企業
- Zivo Bioscience, Inc.
Zivo Bioscience, Inc.ZIVO
時価総額
$2410.9万
PER
| 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | |
| NET LOSS | -2,731,610 | -3,248,405 | -10,095,878 | 680,811 | -5,789,131 | -6,059,627 | -10,038,374 | -14,635,367 | -11,510,166 | -9,105,729 | -9,163,366 | -8,745,293 |
| Stock issued for services rendered | - | - | - | - | - | - | 1,217,369 | 822,001 | 759,378 | 2,302,044 | 32,775 | - |
| Gain of forgiveness of debt and accrued interest | - | - | - | - | - | - | -406,482 | - | - | - | 122,520 | - |
| Employee and director equity-based compensation expense | - | - | - | - | - | - | - | - | - | - | 3 | 3 |
| Non-cash lease expense | - | - | - | - | - | - | - | - | - | - | 22,138 | 79,637 |
| Amortization of deferred R&D obligations - participation agreements | - | - | - | - | - | - | - | - | - | - | -555,745 | 774,025 |
| Prepaid expenses | 443 | - | -63,421 | 40,398 | 19,383 | -1,096 | 1,705 | 7,473 | 666 | 6,672 | -28,125 | 44,338 |
| Security deposits | 1,565 | - | 122,917 | 845 | - | - | - | - | - | - | - | -29,058 |
| Accounts payable | - | - | - | - | - | - | -124,656 | -119,285 | 950,002 | 187,199 | -905,295 | -163,663 |
| Lease liabilities | - | - | - | - | - | - | - | - | - | - | - | -51,695 |
| Accrued liabilities | 13,176 | - | - | - | - | -5,630 | 1,312,188 | 2,098,419 | 1,520,441 | 654,460 | 483,160 | -66,639 |
| Net cash (used) in operating activities | -1,294,128 | - | -2,986,214 | -2,736,046 | -2,296,887 | -2,543,473 | -4,242,891 | -5,006,586 | -3,707,297 | -2,588,415 | -6,803,333 | -7,102,612 |
| Net cash (used) in investing activities | -4,720 | - | -331,377 | - | - | - | - | - | - | - | - | - |
| Proceeds of loans payable, other | 24,306 | - | - | - | 2,067,500 | - | 148,040 | -217,614 | - | - | 190,500 | 628,600 |
| Payment of loans payable, other | - | - | - | - | - | - | - | - | - | - | 190,500 | 628,600 |
| Proceeds from sale of common stock warrants - participation agreements | - | - | - | - | - | - | - | - | - | - | 55,697 | - |
| Expenses related to public offering | - | - | - | - | - | - | - | - | - | - | 2 | - |
| Proceeds from sales of common stock | 617,500 | - | - | - | - | - | - | 3,433,813 | 2,650,000 | 400,866 | 2 | - |
| Net cash provided by financing activities | 1,508,938 | - | 3,763,547 | 2,244,325 | 2,312,093 | 3,033,870 | 4,053,040 | 5,078,342 | 3,664,517 | 2,380,166 | 16 | - |
| Increase (decrease) in cash | - | - | - | - | - | - | - | - | - | - | 9 | -7,102,612 |
| Interest | - | - | - | - | - | - | - | - | - | - | 3,084 | 10,920 |
| Income taxes | - | - | - | - | - | - | - | - | - | - | - | - |